(pral-SEH-tih-nib)
This page contains brief information about pralsetinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Pralsetinib is approved to treat:
- Non-small cell lung cancer that has a RET fusion gene and has spread to other parts of the body. It is used in adults.
- Thyroid cancer that has a RET fusion gene and has spread. It is used in adults and children aged 12 years and older who need systemic therapy, including those who received radioactive iodine and it did not work or is no longer working.¹
¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that pralsetinib provides a clinical benefit in these patients.
Pralsetinib is also being studied in the treatment of other types of cancer.
More About Pralsetinib
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Pralsetinib – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Pralsetinib – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
